Clinical trials: Stage IV Retroperitoneal Sarcoma AJCC v8

Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma

Niraparib for the Treatment of Leiomyosarcoma

• Withdrawn
• Age: 18 years and older
• Phase 2

This phase II trial tests whether niraparib works to shrink tumor in patients with leiomyosarcoma. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged.

Conditions

Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Retroperitoneal Sarcoma AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8

Trial name

NCT05174455

Testing

Niraparib Tosylate Monohydrate

Sponsor

David Liebner, MD